are used in the context of clinician-patient interaction to determine if vaccination may be appropriate for that patient. 4 It is important to understand that a Category B recommendation is a "recommendation, " as opposed to a "non-recommendation, " silence on the topic, or something that can be ignored. The October 2015 ACIP recommendation that the MenB vaccine "may be given" to persons 16 to 23 years of age, with the preferred age being 16 to 18 years, is an example of a Category B recommendation. 5 Why was the MenB vaccine assigned Category B rather than Category A for healthy adolescents? Simply speaking, there was not enough evidence to recommend that all 16-to 18-year-olds receive the vaccine, but there was enough evidence to recommend that adolescents and young adults be given the choice of vaccination, in the context of the provider-patient relationship and joint decision-making. Factors that favored Category B included the low burden of disease and the high cost per quality-adjusted life year saved of a universal program (which would have been implemented with a Category A recommendation), as well as a lack of information about duration of protection, effects on carriage, herd immunity, and strain coverage (serogroup B strains are antigenically diverse).
"Individual clinical decision-making" cannot occur if a patient does not know about the vaccine and the disease. The AAP acknowledges this caveat by encouraging pediatricians to discuss the availability of the MenB vaccine with families, 3 in essence providing the first real guidance on implementing the Category B recommendation. In the absence of such a discussion, disparities could arise between the "information haves" (families who know about the disease and seek vaccination) and the "information have-nots" (those who do not know about the disease or the vaccine). Under Category B, patients should have a choice between being vaccinated or not being vaccinated, a choice that boils down to, at the individual level, the tradeoff between a sore arm and continued vulnerability to a rare but potentially devastating disease. It is noteworthy that, generally speaking, the patient's choice is not whether to spend his or her money; the Patient Protection and Affordable Care Act directs insurance companies to pay first-dollar for both Category A and Category B recommendations, 6 and both categories of recommendations are generally covered under the Vaccines for Children Program.
Providers need to decide how they will approach initiating the discussion about the MenB vaccine (and, indeed, vaccines yet to come that may carry a Category B recommendation). Should they recommend that every 16-to 18-year-old in the practice be vaccinated (a presumptive approach)? Should they present vaccination as an option (a participatory approach) and ask the patient and family to decide? One problem with the latter approach is that there is no way to predict, short of exposure during an outbreak, which healthy adolescents are at risk for invasive serogroup B disease (even college attendance is not a risk factor 5 ). Should the whole practice or health care system adopt a standard, consistent approach or leave the process up to each provider? Either way, we agree with the implication from the AAP's statement: not discussing MenB disease and the vaccine that is currently available should not be an option. 
